ResMed (RMD) and QBE Insurance are positioned as stocks warranting valuation attention in 2026, according to Rask Media analysis. Both companies operate in distinct sectors—medical devices and insurance—creating diversified exposure across health care and financial services verticals. The focus on these two names suggests investor interest in selective value positioning rather than broad market momentum.
ResMed's inclusion reflects continued attention to the health care equipment and IT services space, where recurring revenue streams and aging demographics provide structural tailwinds. QBE's presence indicates property-casualty insurance remains in focus amid persistent pricing dynamics and catastrophe exposure considerations. Neither company signals an immediate catalyst; rather, the analysis suggests a forward-looking valuation lens ahead of 2026 earnings cycles.
The dual mention of ASX-listed entities (Australian Securities Exchange) underscores that institutional attention remains bifurcated across geographic markets. For US-listed counterparts and global investors, RMD's US-listed ADR continues to offer health care diversification and recurring revenue exposure, though the article's Australian focus limits direct correlation signals.
Sector implication: Health Care and Financial Services sectors show modest neutral positioning with valuation-driven interest rather than momentum-based upside. The article's analytical framing—focused on valuation methodology—suggests consolidation rather than expansion expectations for both names.